Polartechnics Limited proprietary self-sampling device, CerviScreen, has now been adapted to test for sexually transmitted infections (STIs) including Chlamydia, Gonorrhoea and Trichomoniasis for both men and women. The new self-sampling target market for the STI device is sexually active men and women aged 15 to 50.
This device provides the population with an opportunity to self-sample for STIs without the need for a prior medical consultation or an invasive physical exam. The Polartechnics device is the world’s first commercially available self-sampling solution.
The STI self-sampling device has been approved for clinical use in Europe, Australia and the US. Furthermore, the device can be used for home use in the US market. Polartechnics is in the process of developing both pathology and distribution contracts in Europe and the US.
Polartechnics took part in the 2004 ANZA Gateway to the US Summit. Read more about the self-sampling device and Polartechnics’ market plans here.